95 filings
Page 5 of 5
6-K
2t1tead
26 Jun 19
Current report (foreign)
5:16pm
6-K
317eln
25 Jun 19
ERYTECH Announces Opening of Operations at its New
12:00am
6-K
0stdkap
7 Jun 19
Reports Financial Results for First Quarter 2019
4:51pm
6-K
v5dnn8 88t
4 Jan 19
Unaudited Interim Condensed Consolidated Statements of Financial Position
8:51am
6-K
4kmwvdp4
17 Jul 18
ERYTECH Pharma Reports Voting Results from
4:56pm
6-K
nujlfrn xmel9sp5k
25 Jun 18
Current report (foreign)
6:06am
6-K
s32lu2s
15 Jun 18
ERYTECH to Present Preclinical and Clinical Data on Use
12:00am
6-K
ngoh8e2 oyecuouy83xu
7 Jun 18
Current report (foreign)
7:03am
6-K
gb185qn m8b
4 Jun 18
ERYTECH to Present Pharmacodynamic Data from
12:00am
6-K
hii9 43q5
14 May 18
Appointment of Alex Dusek as VP of Commercial Strategy
4:57pm
6-K
h3zftnu
12 Apr 18
ERYTECH to Present Results from Phase I Trial of eryaspase in ALL and NewPre-clinical Data at AACR 2018
12:00am
6-K
iu84ikqlytj
12 Mar 18
Reports Financial Results for Full Year 2017
12:00am
6-K
mvy64z2e80rb
13 Feb 18
Erytech Pharma 6-K
12:00am
6-K
1m68b abqr
8 Dec 17
ERYTECH ReportsTop-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
12:00am
6-K
xyh1wbs7hmz23
7 Dec 17
Unaudited Interim Condensed Consolidated Statements of Financial Position
12:00am